N/A N=43 Patient Anxiety Associated With Lymphedema Surveillance Method
Anxiety
Primary: Anxiety — 7.1; 8.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=47 Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer
Arm Lymphedema · Truncal Lymphedema · Breast Cancer
Primary: Arm Volume at End of Study — 2376.52; 2539.93 ml
Phase 4 N=50 Low Level Laser Treatment and Breast Cancer Related Lymphedema
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
N/A N=568 Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Lymphedema
Primary: Number of Participants Who Were Lymphedema-free 18 Months After Randomization — 114; 135 Participants
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 2 N=82 Acupuncture for Chronic Lymphedema
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
Phase 2 N=10 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
Phase 4 N=9 Effect of Exercise on Indocyanine Green (ICG) Lymphography Imaging
Lymphedema
Primary: Time for Initial Disease Pattern to Appear — 5 seconds
N/A N=670 Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
Breast Cancer Related Lymphedema · Covid19
Primary: COVID-19 Vaccination on Contralateral vs Ipsilateral Arm — 432; 435; 331; 122 Participants
N/A N=21 LLLT Combined With CDT in Breast Cancer-Related Lymphedema
Breast Cancer · Lymphedema
Primary: Arm Volume — 1.48; 1.58 cm^3
Phase 2 N=24 Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Breast Cancer
Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…
N/A N=75 Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
Lymphedema · Breast Cancer
Primary: Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy — 19; 21; 22 participants
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=512 T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Breast Cancer
Primary: Number of Participants of Clinically Relevant Toxicities (CRT) — 36; 13; 42; 26 Participants